REDX Stock Overview
Engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Redx Pharma Plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.15 |
52 Week High | UK£0.38 |
52 Week Low | UK£0.04 |
Beta | -0.53 |
11 Month Change | -18.92% |
3 Month Change | -25.00% |
1 Year Change | -53.85% |
33 Year Change | -76.92% |
5 Year Change | 185.71% |
Change since IPO | -82.46% |
Recent News & Updates
Shareholder Returns
REDX | GB Pharmaceuticals | GB Market | |
---|---|---|---|
7D | 62.2% | 0.1% | -0.5% |
1Y | -53.8% | 11.4% | 4.4% |
Return vs Industry: REDX underperformed the UK Pharmaceuticals industry which returned 5.4% over the past year.
Return vs Market: REDX underperformed the UK Market which returned 2.3% over the past year.
Price Volatility
REDX volatility | |
---|---|
REDX Average Weekly Movement | 33.2% |
Pharmaceuticals Industry Average Movement | 7.5% |
Market Average Movement | 4.7% |
10% most volatile stocks in GB Market | 10.7% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: REDX's share price has been volatile over the past 3 months.
Volatility Over Time: REDX's weekly volatility has increased from 17% to 33% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 101 | Lisa Mary Anson | www.redxpharma.com |
Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn’s disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers.
Redx Pharma Plc Fundamentals Summary
REDX fundamental statistics | |
---|---|
Market cap | UK£58.35m |
Earnings (TTM) | -UK£33.16m |
Revenue (TTM) | UK£4.20m |
13.9x
P/S Ratio-1.8x
P/E RatioIs REDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
REDX income statement (TTM) | |
---|---|
Revenue | UK£4.20m |
Cost of Revenue | UK£0 |
Gross Profit | UK£4.20m |
Other Expenses | UK£37.36m |
Earnings | -UK£33.16m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.085 |
Gross Margin | 100.00% |
Net Profit Margin | -789.05% |
Debt/Equity Ratio | 468.9% |
How did REDX perform over the long term?
See historical performance and comparison